Investor Newsletter

Issue 09 2023

MicroPort®

Multiple MicroPort® Business Groups Make an Appearance at SOLACI-SBHCI 2023

The 2023 annual meetings of the Latin American Society of Interventional Cardiology (SOLACI) and the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI) were held in Rio de Janeiro, Brazil from 2-4 August 2023 (SOLACI-SBHCI 2023), drawing interventional cardiology experts from around the world. MicroPort® presented clinical applications of its interventions and devices, which drew many experts.

By attending the SOLACI-SBHCI 2023 conference, MicroPort® was able to captivate experts by demonstrating its exceptional clinical performance and cutting-edge solutions for coronary intervention and transcatheter aortic valve replacement. As a leading medical device group, MicroPort® will continue to merge the techniques and experiences of top experts worldwide and is committed to the research and development of high-end, innovative medical devices to provide more trustworthy and universal access to state-of-the-art solutions that prolong and reshape patient lives everywhere.

MicroPort EP and MicroPort® CRM Participate in the 16th Asia Pacific Heart Rhythm Society Scientific Session

Recently, the 16th Asia Pacific Heart Rhythm Society Scientific Session (APHRS 2023) was held in Hong Kong. MicroPort EP and MicroPort® CRM actively participated in the exhibition and engaged experts in academic discussions.

The booth attracted experts from countries such as the United States, Japan, Australia, Turkey, Kazakhstan, Argentina, Thailand, Vietnam, South Korea, and Indonesia, who visited to experience the performance of these solutions.

The regional nature of the congress presented us the opportunity to share experiences of our portfolio with and between clinicians and distributors across countries. MicroPort® is committed to providing more comprehensive solutions and professional services for patients and physicians worldwide.

MicroPort

MicroPort® Endovastec™'s Three Products in the Aortic Intervention Field Have Been Approved in Thailand

Recently, the Castor™ Branched Aortic Stent-Graft and Delivery System (Castor™ Branched Stent-Graft), the Minos™ Abdominal Aortic Stent-Graft and Delivery System (Minos™ Stent-Graft), and the Hercules™ Thoracic Stent Graft System with Low Profile Delivery System (Hercules™ LP Stent Graft), developed by Endovastec™ have been granted registration approval from the Thailand Food and Drug Administration (TFDA). These three products are the key offerings from Endovastec™ in endovascular intervention for thoracic and abdominal aortic diseases.

The approval of the company's three key products in Thailand's aortic intervention field lays a solid foundation for further expansion into the Southeast Asian market, benefiting more patients. Endovastec™ will also continue to devote itself to promoting its high-quality, innovative products to more countries worldwide, providing better access to state-of-the-art total solutions to vascular circulatory diseases for patients around the globe.



MicroPort® Endovastec™ Achieves Its First Clinical Implantation of Reewarm™ PTX DCB Catheter in Brazil

Recently, Reewarm™ PTX Drug Coated Balloon (DCB) Catheter, developed by Endovastec™, has been successfully implanted for the first time in Brazil, showing the product's continued proliferation in international markets to serve patients worldwide. Dr. Flávio Meireles, Dr. Pedro Vilas Boas, and their team at Paulo Sacramento Hospital in Sao Paulo, Brazil, completed this operation.

The Reewarm™ PTX DCB Catheter is indicated for Percutaneous Transluminal Angioplasty (PTA) in the peripheral vessels. It is intended for the treatment of femoral-popliteal artery stenosis or occlusion. The balloon carries paclitaxel, which can inhibit the proliferation of smooth muscle cells by acting at lesion sites.

The Reewarm™ PTX DCB Catheter is a significant product of Endovastec™ in peripheral artery disease treatment. It was launched in China in 2020 and received market approval from the Brazilian Health Regulatory Agency (ANVISA) in 2022. The Reewarm™ PTX DCB Catheter has successfully treated over 15,000 patients in China, and the first clinical implantation in Brazil marks a new step in the product's international expansion. In the future, Endovastec™ will continue to devote itself to promoting its innovative products to more countries, benefiting patients with peripheral vascular diseases worldwide.

MicroPort

MicroPort® Endovastec™ completes the first clinical implantation of Minos™ Stent Graft System in Azerbaijan

Recently, MicroPort® Endovastec™'s Minos™ Abdominal Aortic Stent-Graft and Delivery System (Minos™) was successfully implanted in the first clinical case at Baku Merkezi Hospital in Azerbaijan. The surgery was performed by Professor Kamuran Musayev and his vascular surgery team.

This marks the entry of Minos™ into its 16th country, following China, Greece, the United Kingdom, Poland, Germany, Brazil, Argentina, and others. To date, Minos™ has successfully treated over 6,000 patients worldwide with abdominal aortic diseases.

In the future, MicroPort® Endovastec™ will continue to dedicate itself to delivering high-quality and innovative products to more countries worldwide, aiming to bring well-being to patients with circulatory diseases across the globe.



MicroPort

MicroPort® SkyWalker™ Completes Europe's First Total Knee Arthroplasty using Evolution® Medial-Pivot Knee System

The SkyWalker™ Orthopedic Surgical Robot (SkyWalker™), developed by MicroPort® NaviBot™ (Suzhou), an associated company of MicroPort® MedBot™, successfully performed Europe's first-ever total knee arthroplasty (TKA) at the University General Hospital of Larissa in Greece, using the Evolution® Medial-Pivot Knee System (Evolution®) developed by MicroPort® Orthopedics. A total of three TKAs were successfully performed using the SkyWalker™ robot at the hospital on the same day.

MicroPort® MedBot™'s Executive Vice-President and Chief Commercial Officer, Mr. Liu Yu, stated: "The successful completion of three consecutive surgeries in a single day, as the first cases in Europe, firmly establishes the reliability and stability of SkyWalker™. This represents an important step for SkyWalker™ in its mission to benefit patients worldwide."

MicroPort EP Receives Approval for FireMagic™ TrueForce™ Ablation Catheter in EU and UK

Recently, MicroPort EP announced that its FireMagic™ TrueForce™ Ablation Catheter (TrueForce™ Ablation Catheter) had successfully obtained CE certification in the European Union and UKCA certification in the United Kingdom.

The TrueForce™ Ablation Catheter, when used alongside MicroPort EP's Columbus™ 3D EP Navigation System and OptimAblate™ Cardiac Generator, is employed for the treatment of drug-refractory recurrent symptomatic paroxysmal atrial fibrillation.

In 2022, the TrueForce™ Ablation Catheter received its initial approval from the NMPA in China. Since then, it has been employed in over 400 radiofrequency ablation surgeries. The recent acquisition of CE certification and UKCA certification marks a significant stride in MicroPort EP's journey. In the future, MicroPort EP will continue to provide high-quality and comprehensive solutions for electrophysiological diagnoses and treatment to more patients worldwide.

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com